Bisphenol-A (BPA) has been making headlines for potential connections with neurologic conditions, obesity, and myriad other health concerns. A recent study published in Human Reproduction looked at whether BPA had a negative impact on fertility.
Bisphenol-A (BPA) has been making headlines for potential connections with neurologic conditions, obesity, and myriad other health concerns. A recent study published in Human Reproduction looked at whether BPA had a negative impact on fertility.
The study drew from patients undergoing IVF/ICSI at Brigham and Women’s Hospital from March 2011 to April 2013. Only oocytes from one cycle per patient were included. If a cycle that resulted in two or more germinal-vesicle stage oocytes was included, one oocyte was randomly assigned to a non-BPA culture for 30 hours and the other oocytes were added to a medium with BPA (20,200 ng/mL or 20 μg/mL). The oocytes were examined with immunofluorescence and confocal microscopy and labeled for tubulin, actin, and chromatin. All specimens were assessed for meiotic stage (n = 292) and those at metaphase II (n =175) were given further classifications according to spindle configurations and chromosome alignment.
The study’s authors found that that as the amount of BPA an oocyte increased, the less likely it was to progress to metaphase II (P= 0.002). Exposed specimens also were more likely to have degenerated (P = 0.01) or undergone spontaneous activation (P = 0.007). BPA-exposed oocytes that reached metaphase II showed a dose-dependent trend for decreased incidence of bipolar spindles (P < 0.0001) and aligned chromosomes (P = 0.002).
The authors did caution that further study is required because they were only able to study a limited sample of oocytes that had been clinically discarded and had failed to mature in vivo despite being exposed to human chorionic gonadotropin.
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Pioglitazone outperforms metformin in IVF for PCOS-related infertility
May 6th 2024A recent double-blind, randomized clinical trial revealed a higher clinical pregnancy rate with pioglitazone compared to metformin in polycystic ovarian syndrome patients undergoing in vitro fertilization, suggesting potential for improved outcomes.
Read More
Reducing multifetal pregnancy through publicly funded IVF programs
April 26th 2024Learn how a mandatory elective single-embryo transfer policy in publicly funded in vitro fertilization programs significantly decreases multifetal pregnancy rates, offering insights into mitigating risks in assisted reproduction.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More